Objective: The aim of this study is to determine the feasibility of a screening method for cervical cancer using an application developed on smartphone to aid visual inspection with acetic acid.
INTRODUCTION
Cervical cancer is the most common cancer in Indian women, accounting for nearly 22.9% of new cancer cases and 20.7% of all cancer-related deaths in the country. 1 Mortality due to cervical cancer is more than 88% in low-income countries, and this by 2030 is predicted to rise to 91.5%. 2 In hospital-based cancer registries (HBCRs), cervical cancer was the leading cause of cancer in Bengaluru and Chennai, the second in Mumbai and Thiruvananthapuram, and the third in Dibrugarh. 3 Most cervical cancer cases are detected in late stage in developing countries primarily due to lack of regular screening programs. According to World Health Organization (WHO), the risk of cervical cancer reduces by 25 to 30% even if screening is done once-in-a lifetime on women in their thirties or forties. 4 There are several screening tests in practice to identify pre-cancerous lesions. Cytology-based Pap-test, visual inspection with acetic acid (VIA), with or without Lugol's iodine (VILI), and the human papilloma virus (HPV)-DNA test are the prominent methods being practiced across the world. In the high-income countries, Pap-test and HPV-DNA based screening programs are highly effective. However, health systems in developing countries are not well-equipped to effectively promote Pap-test based screening for all women. 2 Therefore, VIA has been advocated as a screening technique. A metaanalysis to assess various screening tests in over 58,000 women in India and Africa found VIA and VILI to be reasonably accurate. Each woman underwent VIA and one or more other screening tests; the reference standard was colposcopy with histopathology or a negative colposcopy. 5 The visual inspection with acetic acid showed a sensitivity of 79% [95% confidence interval (95% CI) 73-85] and a specificity of 85% (95% CI 81-89) for cervical intraepithelial neoplasia (CIN)2+. Visual inspection with acetic acid with or without Lugol's iodine was 10% more sensitive and equally specific. Visual inspection with acetic acid with magnification (VIAM) showed similar results as VIA. The Pap smear showed lowest sensitivity for CIN2 + (57%; 95% CI 38-76) but had a higher specificity (93%; 95% CI 89-97). The HPV-DNA by hybrid capture 2 (HC2-assay) showed a sensitivity for CIN2 + of 62% (95% CI 56-68) and a specificity of 94% (95% CI 92-95). The results of visual tests and colposcopy showed a very high correlation. The limitation of this meta-analysis was that because of this correlation and possible overdiagnosis of CIN2+ by pathologists, the sensitivity and specificity of VIA and VILI were overestimated. 5 The result of VIA screening is dependent upon the skill of the health care worker. During a VIA, digital images can be easily captured and saved for subsequent review by colposcopists for a quality check. Currently, mobile phones are commonly available, inexpensive, and have good quality cameras. Using a smartphone device, with an application to capture images during VIA, may be a low-cost scalable screening technique. It is expected to be more objective (with reproducible results) than VIA performed and interpreted only by a health care worker. 6 One such application is developed on an Android-based smartphone and the present study was carried out to see its feasibility for screening women for cervical cancer.
MATERIALS AND METHODS
This prospective study was carried out in two groups of women from March to September 2014. The study was approved by the Institutional Ethics Committee of Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh. Group 1 women (n = 28) were scheduled for colposcopy in the colposcopy clinic of the Department of Obstetrics and Gynaecology of the PGIMER, Chandigarh, India. Group 2 women (n = 202) were attending an outreach screening program in which a mobile van (Asha Jyoti) screens women for cervical cancer, breast cancer, and osteoporosis. Asha Jyoti is a population-based screening program of women in the age group of 30 to 65 years, which aims to ensure early detection of breast cancer, cervical cancer, and osteoporosis. This was initiated jointly by Philips Health care, PGIMER (Chandigarh), and RAD-AID (USA).
The study was designed as open-label, as it was conducted to test the technical feasibility of implementation of the mobile phone based imaging device for screening for cervical cancer in existing health care infrastructure. Women between 30 and 65 years who voluntarily consented to participate were enrolled. Women who had undergone a hysterectomy were excluded. A written consent was obtained from all women. This consent also included consent for publication of study outcome while protecting the identity of women who participated. The confidentiality was maintained by keeping the phone under lock and key by the investigators when not in use. It was used only by the investigators and the two staff nurses of the Asha Jyoti mobile van. Once recorded, the data were encrypted and could be accessed only by the authorized persons. Colposcopy was performed in the colposcopy clinic by two gynecologists trained and practicing for > 10 years in colposcopy using a digital video colposcope (Borze, India, Ltd, Delhi-NCR, India). In the Asha Jyoti van, cervical cancer screening is carried out by health care workers using a similar colopscope to obtain digital images after acetic acid and Lugol's iodine application, which are reviewed by a gynecologist in PGIMER. The women enrolled in the present study underwent colposcopy (in the colposcopy clinic) or routine screening (in the Asha Jyoti van), and during the same examination, images were also obtained by the hand-held mobile phone device (ColpPhon TM ). ColpPhon TM is an
Android-based mobile application that uses the camera and light-emitting diode (LED) flashlight of any mobile with 8MP camera. The application has functionality to register patients, add clinical history, capture images, and send the case history for second review/tele consultation. The app has special features, such as workflow assistance and reminder for timer before acetic acid phase. All images were reviewed independently by two gynecologists and the images obtained by the colposcope were compared with those obtained by the ColpPhon TM . The clinical factors analyzed were visibility of the transformation zone (TZ), acetowhite appearance (ACW), Lugol's iodine uptake, and overall diagnosis. The image quality parameters were brightness, glare, sharpness, and clarity. These were accorded a scale of 1 to 5, with 1 being very poor; 2: poor, 3: average, 4: good, and 5: being excellent.
RESULTS
Among the 230 women screened, CIN was diagnosed on histopathology in six women (CIN 2/3 in five and CIN 1 in one). These six women belonged to the group of 28 women examined in the colposcopy clinic. All six had been identified as abnormal by the colposcope and ColpPhon TM both. by the colposcope. The reasons for inadequate assessment by the ColpPhon TM in the 22 cases that could be assessed adequately by the colposcope were glare (excessive brightness resulting in blurring) in 15 followed by position of the cervix in four and nonvisualization of an acetowhite area in three. Table 4 summarizes detailed results in the colposcopy clinic (n = 28). Among these 28 cases, two could not be assessed technically by the colposcope due to a type 3 transformation zone. Among the 26 cases assessed adequately by the colposcope, 12 with acetowhite area, 4 with acetowhite and iodine-negative areas, and 2 with iodine-negative areas were identified by the colposcope and the ColpPhon TM both. The remaining eight cases had normal findings by the colposcope of which five were also normal by the ColpPhon TM and three could not be assessed by the ColpPhon TM due to blurred images or glare. The histopathological diagnosis of CIN 1 in one and CIN 2-3 was reported in five cases; all six had been identified as abnormal by the colposcope and ColpPhon TM both. Table 3 . Women with abnormal finding by the colposcope were 31 (17 with acetowhite area, 7 with acetowhite and iodine-negative areas and 7 with iodine-negative areas) of whom 29 were identified by the ColpPhon TM as well. The ColpPhon TM missed acetowhite areas in three women, though one of these three was identified as abnormal due to an iodine-negative area. However, in these 31 women with abnormal colposcopy findings, the PAP smear was either normal or inflammatory in 30 of 31. The histopathology in 12 of these women who underwent a cervical biopsy was benign (chronic cervicitis, squamous metaplasia, polyp). The final diagnosis made on images acquired from each device had an agreement in 90% (208/230) women. Among the colposcopy clinic, the final diagnosis made on images acquired from each device had an agreement in 89% (25/28) women. Among the Asha Jyoti van cases, the final diagnosis made on images acquired from each device had an agreement in 90.5% (183/202) women. Importantly, an abnormality confirmed as CIN by histopathology in six women had been identified by the colposcope and the ColpPhon TM both. The three women in whom an acetowhite area, which was reported on colposcopy but missed by the ColpPhon TM , had normal 
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Pap smears. Biopsy was done in only one of these and reported as chronic cervicitis.
DISCUSSION
In the present study, we assessed the feasibility of digital technology by using a smartphone camera (ColpPhon TM ) to capture images of the cervix after application of acetic acid and Lugol's Iodine. These images were reviewed subsequently by two colposcopists and compared with images obtained in the same sitting with a digital video colposcope in a colposcopy clinic (n = 28) and in an outreach setting by trained nurses (n = 202). This process is equivalent to recording digital images of the cervix while performing cervical cancer screening by VIA or VILI.
We observed that the overall clarity of the image obtained by the ColpPhon TM was "good" or "excellent" in 82% of the cases in whom the colposcopic images were "good" or "excellent" (184/225). The final diagnosis made on images acquired from each device had an agreement in 90% (208/230) cases, as the ColpPhon TM images rated as "average" (score = 3) in 24 cases were also appropriate for interpretation. This was similar among the colposcopy clinic (agreement in 89%; 25/28) cases and the Asha Jyoti van (agreement in 90.5%; 183/202) cases, which suggests that this technology is likely to work well in the hands of health care workers performing a VIA screening in out-reach areas. An important observation was that an abnormality that was confirmed as CIN by histopathology in six women had been identified by the colposcope and the ColpPhon TM both. In three women, acetowhite area was reported on colposcopy but not by the ColpPhon TM . The Pap smear was normal in all three and biopsy in one of them showed chronic cervicitis. The other two women were not biopsied, as the colposcopists interpreted it as a metaplastic change. Thus, a clinically relevant abnormality was identified by the colposcope and ColpPhon TM both.
One limitation of the ColpPhon TM was blurring due to glare (excessive brightness) in 15 women in whom the coloposcope image was appropriate for interpretation. This can be improved by optimizing the camera, reducing the brightness, and incorporating features such as auto-adjustment for better image quality. The reflection of light by a metal speculum can also be taken into account while making these changes. Another limitation was that the position of the cervix precluded proper visualization in four women. This may be overcome to a certain extent by the skill of the health care personnel and expertise in manipulating the speculum to bring the cervix into view. Capturing images of the cervix to review them subsequently for an abnormality has been reported earlier. Chen A total of eight cervical neoplasia cases were detected by histopathology: two CIN1, two CIN2, two CIN3, and two invasive cancers. The on-site physician detected four of six CIN2+ lesions. A missed cancer by the on-site physician was detected by the D-VIA consensus among physicians in Geneva. Overall, two CIN2+ were missed and 18 healthy women were unnecessarily treated on-site. This pilot study supported the use of telemedicine for off-site diagnosis of CIN, with diagnostic performance similar to those achieved on-site. Further studies need to determine whether incorporation of smartphones to capture images of the cervix after acetic acid application in the cervical cancer screening program can improve screening efficiency in resource-poor countries. The present study showed the feasibility of using low-cost technology for cervical cancer screening in the form of a mobile smartphone camera to capture images during a VIA screening. The use of this technology does not require any sophisticated training. It can be used in areas having erratic access to electricity. The reviewing clinician is likely to be able to identify a clinically relevant abnormality from the captured images. Additional benefits would be in the form of medical records documentation and a quality check on the health care worker's capability and technique of performing VIA. Viewing the images captured by the health care workers would tell the reviewer whether their training and skill to perform a speculum examination and visualize the cervix in its entirety is appropriate. Feedback about the VIA-positive or negative cases reported by the health care workers would improve their skills.
CONCLUSION
The present study demonstrates the feasibility of incorporating a mobile smartphone device to capture images of the cervix during visual inspection after acetic acid application. It offers portability, has low power requirements, and has negligible maintenance. In addition, the cost per test is low and it may help in medical records documentation and keep a quality check on the VIA screening being performed by health care workers. This simple technology may improve cervical cancer screening in resource-poor countries.
